Betta Pharmaceuticals
Betta Pharmaceuticals, established in 2003, is a leading Chinese pharmaceutical company specializing in the research, development, manufacturing, and marketing of innovative medicines. Its primary focus is on treating severe diseases like malignant tumors, diabetes, and cardio-cerebrovascular diseases. Betta's flagship product, Icotinib Hydrochloride (Conmana), is a pioneering targeted anti-cancer drug developed in China, used for treating non-small-cell lung cancer. The company has a strong pipeline with over 20 new drug development projects and holds more than 100 authorized patents. Betta Pharmaceuticals is headquartered in Hangzhou, with additional facilities in Beijing, and employs nearly 1,000 people, including many returned PhD holders. It has successfully listed on the GEM of the Shenzhen Stock Exchange and has received numerous awards for its innovative work, including the First Prize of National Prize for Progress in Science and Technology.
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
8 past transactions
Reprogenix
Series A in 2024
Reprogenix is a pioneering medical technology company specializing in regenerative stem cell medicine. It initially focused on stem cell therapy for diabetes and has since expanded its scope to develop advanced biomedical solutions for various disease areas. The company leverages proprietary human pluripotent stem cell technology to create innovative, regenerative treatments.
Gaowei Medicine
Angel Round in 2023
Gaowei Medicine is a drug discovery platform for developing new drugs for key intractable diseases such as cancer and neurological diseases.
C4 Therapeutics
Post in 2023
C4 Therapeutics is a biopharmaceutical company developing targeted protein degradation therapies using its proprietary Degronimid platform. This platform enables the selective destruction of disease-causing proteins, expanding the scope of treatable conditions and potentially reducing drug resistance. The company focuses on oncology indications and has strategic collaborations with industry leaders.
E-nitiate Biopharmaceuticals
Angel Round in 2022
E-nitiate Biopharmaceuticals is committed to the development of innovative drugs for autoimmune diseases, through independent research and development, and strategic collaborations, to address unmet medical needs and to improve the quality of human life.
CentryMed
Series A in 2022
CentryMed is a biotechnology company specializing in the development of antibody drugs for the treatment of tumors and autoimmune diseases. It has created a proprietary dual-antibody platform and constructed its own human dAb libraries, which are protected by independent intellectual property rights. This innovative approach addresses critical issues related to drug efficacy and the side effects commonly associated with antibody therapies. As of 2021, CentryMed has successfully developed over 20 unique and differentiated antibody drugs aimed at targeting various solid tumors and different stages of immune diseases, thereby addressing significant clinical and patient needs.
Capio Biosciences
Series A in 2017
Capio Biosciences is a biotechnology company dedicated to advancing oncology diagnostics to enhance patient care and outcomes. The company is developing an innovative platform known as CapioCyte™, which focuses on the capture of circulating tumor cells (CTCs) from whole blood. Utilizing a unique combination of biomimetic cell rolling and dendrimer-mediated multivalent cell capture, CapioCyte™ offers significantly improved sensitivity for capturing CTCs compared to existing technologies. This platform not only facilitates the enrichment of CTCs for further molecular analysis, including FISH, RNA-Seq, and NGS, but also holds promise for future applications in clinical patient management. Through its personalized treatment therapies, Capio Biosciences aims to assist healthcare providers in effectively managing cancer treatment by enabling the removal of cancer cells from patients' bodies via liquid biopsy techniques.
Hangzhou DAC Biotech Co.
Angel Round in 2015
Hangzhou DAC Biotech Co., Ltd., established in 2012 and headquartered in Hangzhou, China, specializes in the development of cancer treatment drugs. The company offers an antibody-drug conjugate (ADC) platform featuring over 50 intelligent linkers for site-specific conjugation and five types of high-activity small molecule compounds with varied mechanisms. Additionally, DAC Biotech provides advanced technologies for antibody discovery, engineering transformation, and production process optimization. Their services include comprehensive ADC drug evaluation in vivo and in vitro, drug structure confirmation, and analytical method development and verification.
Xcovery
Private Equity Round in 2014
Xcovery LLC is a biopharmaceutical company based in Palm Beach Gardens, Florida, founded in 2006. It specializes in the development of targeted oncology therapies designed to address various advanced tumors. The company is known for its lead compound, X-396, a small molecule that inhibits anaplastic lymphoma kinase, along with other kinase inhibitors targeting MET and PI3K/mTOR pathways. Xcovery aims to create low-toxicity oral drugs that facilitate continuous therapy without the need for dosing interruptions, thereby enhancing treatment efficacy and safety for cancer patients. This approach allows for a broader therapeutic window and the potential for combination therapies without the toxicity associated with current treatments. The leadership team includes experienced professionals from notable biotech backgrounds, contributing to the company's innovative research and development efforts in oncology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.